Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab ± ipilimumab as maintenance in extensive-stage small cell lung cancer
CTR20170694Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Started Jul 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20170694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170694.